Psoriasis
📧 Sign up to get email alerts when something new happens for Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis [NA]
This clinical trial update discusses the role of Lyn tyrosine kinase and caspase-cleaved forms in psoriasis, with the study status listed as…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Deucravacitinib Adherence Study [NA]
Clinical trial update for NCT05570955 evaluating adherence to deucravacitinib in psoriasis. The study is currently active but not recruiting…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps
A safety study of Remsima SC for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis remains active but not rec…
-
EMA approval · 2026-03-30EMA Authorised: Imuldosa (ustekinumab) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Imuldosa (ustekinumab) from Accord Healthcare S.L.U. for Crohn's disease, psoriasis, and psoriatic …
-
EMA approval · 2026-03-30EMA Authorised: Uzpruvo (ustekinumab) — Stada Arzneimittel AG
EMA authorised Uzpruvo (ustekinumab) for the treatment of psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-30Clinical Trial Update: Guselkumab Immunogenetics [Phase 4]
Phase 4 clinical trial update for guselkumab investigating immunogenetics in psoriasis, including guttate and plaque psoriasis, currently no…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: Multi-Center PAMPA Study [Phase 4]
A phase 4 multi-center PAMPA study sponsored by NYU Langone Health is evaluating psoriasis and is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Impact of Clinical and Psychological Factors on Satisfaction With Treatment in Psoriatic Patients on Biological Therapy
A completed clinical trial evaluating how clinical and psychological factors affect patient satisfaction with biological therapy in psoriasi…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis [Phase 2]
Phase 2 study to evaluate D-2570 for moderate to severe plaque psoriasis; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis [NA]
A clinical trial update from the University of Pennsylvania on preventing cardiovascular disease and mortality in patients with psoriasis or…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: An AI-Based Erythema Measurement System for Psoriasis Lesions
An upcoming study from Khon Kaen University aims to validate an AI-based erythema measurement tool for psoriasis lesions. Recruitment has no…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of subcutaneous tildrakizumab in adults with moderate to severe genital psoriasis;…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients [Phase 4]
A Phase 4 clinical trial is evaluating the combination of Metformin and Secukinumab for moderate-to-severe plaque psoriasis in overweight or…
-
EMA label_change · 2026-03-23EMA Authorised: Tremfya — Janssen-Cilag International NV
EU authorises Tremfya to treat psoriasis, Crohn's disease, and ulcerative colitis.
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Smart Phone Delivered Cognitive Behavioral Therapy for Adults With Psoriasis and Co-Morbid Depression Symptoms [NA]
A completed trial evaluated the effectiveness of a smartphone-delivered cognitive behavioral therapy program for adults with psoriasis and c…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease [Phase 4]
A Phase 4 clinical trial update notes a study on how salt intake affects sodium in the skin and inflammatory skin diseases, focusing on atop…
-
EMA approval · 2026-03-20EMA Authorised: Apremilast Accord (apremilast) — Accord Healthcare S.L.U.
The EMA has authorised Accord Healthcare's apremilast product (Apremilast Accord) for psoriatic arthritis, psoriasis, Behçet's syndrome, and…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
This document summarizes an ongoing longitudinal observational study of patients undergoing therapy for IMISC (NCT03661866) across several i…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Improving Disease Severity [NA]
A Wake Forest University Health Sciences-sponsored clinical trial update reports a completed study aimed at improving disease severity in ps…
-
EMA approval · 2026-03-19EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
EMA authorised Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases, expanding treatment options in rheumatoid …
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: A Trial of SHR-1139 in Healthy Volunteers [Phase 1]
Phase 1 trial of SHR-1139 in healthy volunteers; psoriasis is listed as a condition but participants are healthy, and the study is active bu…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
This is a clinical trial update for CONDYPSO. It investigates whether anti-psoriatic biologics affect the risk of anogenital warts (condylom…
-
CLINICAL_TRIALS other · 2026-03-18Clinical Trial Update: A Randomised Controlled Trial of ePROM-Guided Flexible Scheduling in Dermatology [NA]
This is a randomized controlled trial assessing ePROM-guided flexible scheduling in dermatology, targeting eczema (atopic dermatitis), urtic…
-
EMA approval · 2026-03-17EMA Authorised: Bimzelx (bimekizumab) — UCB Pharma S.A.
The EMA authorised Bimzelx (bimekizumab) from UCB Pharma S.A. for psoriasis, with a decision date of 28 April 2025.
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis [Phase 4]
A Phase 4 clinical trial evaluating dose reduction of IL-17 and IL-23 inhibitors in psoriasis has completed.